- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.09. | HAO WEN HLDGS (08019): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS | - | HKEx | ||
| HAO WEN HOLDINGS Aktie jetzt für 0€ handeln | |||||
| 18.09. | HAO WEN HLDGS (08019): INTERIM REPORT 2025 | 1 | HKEx | ||
| 18.09. | HAO WEN HLDGS (08019): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS | 1 | HKEx | ||
| 28.08. | HAO WEN HLDGS (08019): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025 | 3 | HKEx | ||
| 18.08. | HAO WEN HLDGS (08019): DATE OF BOARD MEETING | 1 | HKEx |
5 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRIGHT MINDS BIOSCIENCES | 82,12 | -3,00 % | Cantor Fitzgerald bestätigt "Overweight" für Bright Minds Biosciences und sieht Potenzial in Hauptwirkstoff BMB-101 | ||
| BIOHAVEN | 11,145 | +3,96 % | Biohaven Ltd.: Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder | NEW HAVEN, Conn., Dec. 24, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization... ► Artikel lesen | |
| HARROW | 50,09 | -0,14 % | Harrow, Inc.: Harrow Health, Inc. Announces Closing of Acquisition of Melt Pharmaceuticals | NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 5,990 | +0,34 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Broadens Patent Estate for Anaphylm | New patents extend protection for Anaphylm into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe... ► Artikel lesen | |
| UNIVERSE PHARMACEUTICALS | 5,620 | +31,00 % | Universe Pharmaceuticals INC - 6-K, Report of foreign issuer | ||
| ETON PHARMACEUTICALS | 16,830 | -0,94 % | Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution) | - NDA assigned a Target Action Date of February 25, 2026 -- Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 12,950 | -0,23 % | Astria Therapeutics, Inc. - 8-K, Current Report | ||
| MILESTONE PHARMACEUTICALS | 2,080 | +0,48 % | Milestone Pharmaceuticals Inc.: Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) | First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables... ► Artikel lesen | |
| INHIBIKASE THERAPEUTICS | 1,990 | +20,61 % | Inhibikase: H.C. Wainwright startet Coverage mit "Buy" und 385 % Kurspotenzial | ||
| LB PHARMACEUTICALS | 21,530 | -2,14 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer | NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for... ► Artikel lesen | |
| VYNE THERAPEUTICS | 0,588 | +0,94 % | VYNE Therapeutics: +167% für den NBC! | Kurz vor Weihnachten ist schon wieder Bescherung im No Brainer Club: VYNE Therapeutics liefert nach einem Top-Deal satte +167% Rendite innerhalb weniger Monate. Die Weihnachtsgeschenke der NBC-Mitglieder... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 0,305 | +9,71 % | Reviva Pharmaceuticals: Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia | Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 7,570 | -5,38 % | Kazia Therapeutics Limited: Kazia Therapeutics Regains Full Nasdaq Listing Compliance | Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength
SYDNEY, Dec. 22, 2025 /PRNewswire/ -- Kazia Therapeutics... ► Artikel lesen | |
| LIPOCINE | 5,230 | +12,47 % | Lipocine Inc.: Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone | Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026
Topline results on track for the second quarter of 2026
SALT LAKE CITY... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 2,560 | +4,92 % | New to The Street Broadcasts Nationwide Tonight on Bloomberg Television Featuring NeOnc, Metaterra Holdings Inc., CISO Global, and NRx Pharmaceuticals | Commercial sponsors are, Sustainable Green Team (SGTM) , Synergy CHC ($SNYR), DataVault AI ($DVLT),ACURX ($ACXP) ,($PETV) and Aeries Technology ($AERT) NEW YORK CITY, NEW YORK / ACCESS Newswire / December... ► Artikel lesen |
HAO WEN HOLDINGS LIMITED gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HAO WEN HOLDINGS LIMITED finden Sie auf Wallstreet Online.